1. Search Result
Search Result
Results for "

GP

" in MedChemExpress (MCE) Product Catalog:

461

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

13

Biochemical Assay Reagents

53

Peptides

16

Inhibitory Antibodies

56

Natural
Products

260

Recombinant Proteins

36

Isotope-Labeled Compounds

139

Antibodies

3

Click Chemistry

33

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1569
    LCMV gp33-41
    3 Publications Verification

    LCMV GP(33-41) M-peptide; GP33 epitope

    Arenavirus Infection Inflammation/Immunology
    LCMV gp33-41, the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41
  • HY-15037
    Diclofenac Sodium
    20+ Cited Publications

    GP 45840

    COX Apoptosis Inflammation/Immunology Cancer
    Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
    Diclofenac Sodium
  • HY-B0114
    Oxcarbazepine
    2 Publications Verification

    GP 47680

    Sodium Channel Apoptosis Neurological Disease Cancer
    Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
    Oxcarbazepine
  • HY-P2560
    LCMV GP (61-80)
    1 Publications Verification

    Arenavirus Infection Inflammation/Immunology
    LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4 + T-cell response .
    LCMV GP (61-80)
  • HY-P5381
    gp91 ds-tat
    1 Publications Verification

    NADPH Oxidase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase TRP Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease .
    gp91 ds-tat
  • HY-15037R

    GP 45840 (Standard)

    Reference Standards COX Apoptosis Inflammation/Immunology Cancer
    Diclofenac (Sodium) (Standard) is the analytical standard of Diclofenac (Sodium). This product is intended for research and analytical applications. Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells , and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively . Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade .
    Diclofenac Sodium (Standard)
  • HY-121488

    Interleukin Related Neurological Disease
    GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity .
    GP130 receptor agonist-1
  • HY-137680

    Diguanosine tetraphosphate

    Endogenous Metabolite Others
    GP4G (Diguanosine tetraphosphate) is a symmetrical bis-diphospho nucleoside that can be isolated from the cysts of Artemia salina. GP4G is an epithelial cell and hair growth regulator .
    GP4G
  • HY-108506
    Licarbazepine
    1 Publications Verification

    BIA 2-005; GP 47779

    Sodium Channel Neurological Disease
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
    Licarbazepine
  • HY-P1585
    Gp100 (25-33), human
    1 Publications Verification

    HGP100 (25-33)

    MHC Cancer
    Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma .
    Gp100 (25-33), human
  • HY-176294

    Interleukin Related Others
    GP130 modulator-2 (Compound A5) is a GP130 modulator. GP130 modulator-2 can be used for research of disease associated with gp130 activity .
    GP130 modulator-2
  • HY-110050

    Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .
    GP1a
  • HY-U00116

    Adenosine Receptor Cardiovascular Disease
    GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia.
    GP531
  • HY-147280

    GP-2250

    Apoptosis Cancer
    Misetionamide is an orally oxathiazin-like compound. Misetionamide is a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with antineoplastic activity. Misetionamide can be used for the research of cancer .
    Misetionamide
  • HY-P0323A
    GP(33-41) TFA
    1 Publications Verification

    LCMV GP(33-41) C-peptide TFA

    Arenavirus Infection
    GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. GP(33-41) TFA can upregulate H-2D b molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM .
    GP(33-41) TFA
  • HY-19259

    Adenosine Kinase Neurological Disease
    GP3269 is a selective and orally active human adenosine kinase (AK) inhibitor with an IC50 of 11 nM against human adenosine kinase. GP3269 increases adenosine levels at epileptic foci, activates A1 receptors on excitatory neurons, and exhibits anticonvulsant activity in rats. GP3269 does not induce hemodynamic effects including changes in blood pressure or heart rate in rats. GP3269 can be used for epilepsy-related research .
    GP3269
  • HY-P1569A
    LCMV gp33-41 TFA
    3 Publications Verification

    LCMV GP(33-41) M-peptide TFA; GP33 epitope TFA

    Arenavirus Inflammation/Immunology
    LCMV gp33-41 (TFA), the carboxyl-extended 9-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes .
    LCMV gp33-41 TFA
  • HY-P1585A
    Gp100 (25-33), human TFA
    1 Publications Verification

    HGP100 (25-33) TFA

    MHC Cancer
    Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma .
    Gp100 (25-33), human TFA
  • HY-173162

    P-glycoprotein Potassium Channel Cardiovascular Disease Cancer
    GPV0057 (Compound 5d) is a selective and potent P-glycoprotein (P-gp) inhibitor. GPV0057 is also a selective potassium channel Kir2.1 activator. GPV0057 competitively binds to the substrate-binding site of P-gp, inhibiting ATP-dependent drug efflux to reverse multidrug resistance in tumor cells. GPV0057 can also stabilizes the open state of Kir2.1 and promotes potassium ion influx. GPV0057 is promising for research of tumors with high P-gp expression, Kir2.1-deficient diseases such as heart failure and Andersen-Tawil Syndrome .
    GPV0057
  • HY-159742

    Interleukin Related Neurological Disease Inflammation/Immunology
    GP130 modulator-1 (compound A33) is a gp130 signaling pathway modulator. GP130 modulator-1 can be used in the study of inflammatory and degenerative disorders .
    GP130 modulator-1
  • HY-143744

    GP681; Cap-dependent endonuclease-IN-3

    Endonuclease Influenza Virus Infection
    Suraxavir marboxil (GP681; Cap-dependent endonuclease-IN-3) is a PA subunit cap-dependent endonuclease inhibitor with antiviral activity. Suraxavir marboxil inhibits PA subunit cap-dependent endonuclease activity and inhibits influenza A and/or influenza B viral replication. Suraxavir marboxil can be used alone or in combination with other anti-influenzal agents for the prevention of influenza A and/or influenza B viral infectious diseases. Suraxavir marboxil can be used for the research of influenza A and/or influenza B viral infectious diseases .
    Suraxavir marboxil
  • HY-15037S2

    GP 45840-13C6

    Isotope-Labeled Compounds COX Apoptosis Inflammation/Immunology
    Diclofenac- 13C6 (Sodium) is the 13C6 labeled Diclofenac (Sodium). Diclofenac Sodium (GP 45840) is a potent and nonselective anti-inflammatory agent, acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, and 5.1 and 0.84 μM for ovine COX-1 and COX-2, respectively. Diclofenac Sodium induces apoptosis of neural stem cells (NSCs) via the activation of the caspase cascade.
    Diclofenac-13C6 sodium
  • HY-175838

    P-glycoprotein Cancer
    P-gp-IN-32 is a P-glycoprotein (P-gp) inhibitor. P-gp-IN-32 exhibits low cytotoxicity and potent multidrug resistance (MDR) reversal activity against Doxorubicin (HY-15142A) in MCF7/ADR cells (IC50 = 0.11 μM, reversal fold (RF) = 215.9). P-gp-IN-32 can bind to P-gp directly, induce a conformation change of P-gp and inhibit the efflux function. P-gp-IN-32 can be used for the research of cancer, such as breast cancer .
    P-gp-IN-32
  • HY-RS05607

    Small Interfering RNA (siRNA) Others

    GP1BA Human Pre-designed siRNA Set A contains three designed siRNAs for GP1BA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    GP1BA Human Pre-designed siRNA Set A
    GP1BA Human Pre-designed siRNA Set A
  • HY-159857

    GP(2′-5′)Ap(3′) sodium; 2'5'-GPAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium

    Nucleoside Antimetabolite/Analog
    Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
    Gp(2′-5′)Ap sodium
  • HY-108506R

    BIA 2-005 (Standard); GP 47779 (Standard)

    Reference Standards Sodium Channel Neurological Disease
    Licarbazepine (Standard) is the analytical standard of Licarbazepine. This product is intended for research and analytical applications. Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects .
    Licarbazepine (Standard)
  • HY-139099

    GP3G

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Cancer
    Diguanosine 5′-triphosphate (Gp3G) is a dinucleoside triphosphates. Diguanosine 5′-triphosphate also is a virus-specific oligonucleotide. Diguanosine 5′-triphosphate is needed for the synthesis of RNA during the transcription process .
    Diguanosine 5′-triphosphate
  • HY-112528

    GP-NPEA

    Endogenous Metabolite Metabolic Disease
    Glycerophospho-N-palmitoyl ethanolamine (GP-NPEA) is a metabolic precursor of palmitoyl ethanolamide PEA (HY-157829). Glycerophospho-N-palmitoyl ethanolamine decreases in the cortex of CUMS rats, which may be related to a disorder in the endocannabinoid system arising after the onset of depression .
    Glycerophospho-N-palmitoyl ethanolamine
  • HY-B0114R

    GP 47680 (Standard)

    Reference Standards Sodium Channel Apoptosis Neurological Disease Cancer
    Oxcarbazepine (Standard) is the analytical standard of Oxcarbazepine. This product is intended for research and analytical applications. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
    Oxcarbazepine (Standard)
  • HY-U00191

    Adrenergic Receptor Cardiovascular Disease
    GP2-114 (GP-2-114) produces current-dependent cardiovascular action when administered by transdermal iontophoresis.
    GP2-114
  • HY-144730

    HIV Inflammation/Immunology
    gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with an IC50 of 2.2 µM and CC50 of 100.90 µM. gp120-IN-1 shows anti-HIV-1 activity. gp120-IN-1 shows cytotoxicity in a dose dependent manner in SUP-T1 cells. gp120-IN-1 shows inhibition of gp120-mediated virus enter into cells .
    gp120-IN-1
  • HY-144366

    P-glycoprotein Cancer
    P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .
    P-gp inhibitor 3
  • HY-P0323

    LCMV GP(33-41) C-peptide

    Arenavirus Infection
    GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus, and can upregulate H-2D b molecules at the RMA-S (Db Kb) cell surface with a SC50 of 344 nM .
    GP(33-41)
  • HY-178466

    Microtubule/Tubulin P-glycoprotein Apoptosis Cancer
    Tubulin polymerization/P-gp-IN-1 is a Tubulin polymerization/P-gp dual inhibitor. Tubulin polymerization/P-gp-IN-1 inhibits tubulin polymerization and induces G2/M arrest and apoptosis. Tubulin polymerization/P-gp-IN-1 reverses MDR by inhibiting P-gp efflux function. Tubulin polymerization/P-gp-IN-1 has dual functions: direct antitumor activity and reversal of P-gp-mediated Cisplatin (HY-17394) resistance. Tubulin polymerization/P-gp-IN-1 stable binds to the tubulin CBS (ΔG = −12.4 kcal/mol) and the P-gp hydrophobic lumen (ΔG = −10.8 kcal/mol). Tubulin polymerization/P-gp-IN-1 can be used for the study of drug-resistant cervical cancer .
    Tubulin polymerization/P-gp-IN-1
  • HY-P4055

    HIV Infection Inflammation/Immunology
    GP120, HIV-1 MN is a peptide. GP120, HIV-1 MN can be used for the research of HIV infection .
    GP120, HIV-1 MN
  • HY-139099B

    GP3G triammonium

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Cancer
    Diguanosine 5′-triphosphate (Gp3G) triammonium is a dinucleoside triphosphates. Diguanosine 5′-triphosphate triammonium also is a virus-specific oligonucleotide. Diguanosine 5′-triphosphate triammonium is needed for the synthesis of RNA during the transcription process .
    Diguanosine 5′-triphosphate triammonium
  • HY-B0114S

    GP 47680-d4

    Isotope-Labeled Compounds Sodium Channel Apoptosis Neurological Disease Cancer
    Oxcarbazepine-d4 (GP 47680-D4) is the deuterium labeled Oxcarbazepine. Oxcarbazepine is a sodium channel blocker . Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines . Anti-cancer and anticonvulsant effects .
    Oxcarbazepine-d4
  • HY-108506S2

    BIA 2-005-d4-1; GP 47779-d4-1

    Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Licarbazepine-d4-1 is deuterium labeled Licarbazepine. Licarbazepine (BIA 2-005; GP 47779)?is a?voltage-gated sodium channel?blocker?with?anticonvulsant?and?mood-stabilizing?effects .
    Licarbazepine-d4-1
  • HY-P10631

    HSP Inflammation/Immunology
    Gp96-II is a gp96-blocking peptide that antagonizes gp96-mediated LPS(HY-D1056)-induced cytokine production. Gp96-II can be utilized in research on inflammatory disease .
    gp96-II
  • HY-123466

    Drug Derivative Influenza Virus Infection
    GP-1681 is a Beraprost sodium (HY-13569A) analogue. GP-1681 can be used in the research of influenza A H5N1 infection .
    GP-1681
  • HY-P5695

    Bacterial Infection
    GP-2B is an antimicrobial peptide. GP-2B shows antibacterial activity against Gram-positive strain (MIC: 8-128 μg/mL for S. aureus and Enterococcus faecalis) .
    GP-2B
  • HY-P991583

    FGFR ERK Cancer
    GP369 is a humanized FGFR2-IIIb-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .
    GP369
  • HY-144731

    HIV Inflammation/Immunology
    gp120-IN-2 (compound 4i) is a potent HIV-1 gp120 inhibitor with an IC50 of 7.5 µM and CC50 of 112.93 µM. gp120-IN-2 shows anti-HIV-1 activity. gp120-IN-2 shows cytotoxicity in a dose dependent manner in SUP-T1 cells .
    gp120-IN-2
  • HY-168072

    Interleukin Related Apoptosis Autophagy Cancer
    GP130-IN-1 (compound 49) is a potent GP130 inhibitor with significant in vitro antitumor activity and higher selectivity than Bazedoxifene (HY-A0031). GP130-IN-1 induces ultrastructural changes in cells, causing cell cycle arrest in the G0/G1 phase in a time-dependent manner and triggering apoptosis and autophagy. GP130-IN-1 can be used in the study of triple-negative breast cancer .
    GP130-IN-1
  • HY-175522

    P-glycoprotein Apoptosis Cancer
    P-gp-IN-31 is a P-glycoprotein (P-gp) inhibitor with IC50 values of 0.42 μM for KB cells and 0.43 μM for MDR KBvin cells. P-gp-IN-31 can pass P-gp-mediated drug efflux mechanisms and shows collateral sensitivity via P-gp downregulation. P-gp-IN-31 inhibits cell proliferation, induces apoptosis and arrests the cell cycle at G2/M phase. P-gp-IN-31 can be used for the research of cancer, such as multidrug-resistant (MDR) malignancies .
    P-gp-IN-31
  • HY-176193

    P-glycoprotein Cancer
    P-gp modulator-7 (Compound 9e) is a P-glycoprotein (P-gp) inhibitor. P-gp modulator-7 occupies the channel entrance of P-gp with a unique T-shaped configuration, hindering the peristaltic extrusion mechanism of transmembrane domains TM12 and TM9, thereby inhibiting P-gp from pumping drugs out of cells and reversing the multidrug resistance (MDR) of tumor cells. P-gp modulator-7 is promising for research of cancers .
    P-gp modulator-7
  • HY-164675

    HIV Infection
    gp120-IN-3 (Compound 11) is a HIV-1 gp120 inhibitor with an IC50 value of 1.64 nM, which can be utilized in HIV research .
    gp120-IN-3
  • HY-162040

    P-glycoprotein Cancer
    P-gp inhibitor 17 (compound 2g) is a P-gp inhibitor directly interacted with the transmembrane domain of P-gp. P-gp inhibitor 17 can be used for P-gp-mediated multidrug-resistant in tumor cells study .
    P-gp inhibitor 17
  • HY-P1796A

    Transmembrane Glycoprotein Cancer
    Gp100 (619-627) acetate is amino acids 619 to 627 fragment of human melanoma antigen glycoprotein 100 (gp100). Gp100 has been a widely studied target for melanoma immunotherapy .
    Gp100 (619-627) acetate
  • HY-177580

    Integrin Cardiovascular Disease
    GP1 precursor has high affinity to GPIIb/IIIa receptors of activated platelets. GP1 precursor can be radiolabeled with [ 18F] and used as a PET Tracer for visualizing active platelet aggregation at the molecular level. GP1 precursor can be used for the detection of Thrombi .
    GP1 precursor

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: